207 related articles for article (PubMed ID: 32635272)
1. Water-Soluble
Nakagawa F; Kawashima H; Morita T; Nakamura H
Cells; 2020 Jul; 9(7):. PubMed ID: 32635272
[TBL] [Abstract][Full Text] [Related]
2. Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats.
Kanemitsu T; Kawabata S; Fukumura M; Futamura G; Hiramatsu R; Nonoguchi N; Nakagawa F; Takata T; Tanaka H; Suzuki M; Masunaga SI; Ono K; Miyatake SI; Nakamura H; Kuroiwa T
Radiat Environ Biophys; 2019 Mar; 58(1):59-67. PubMed ID: 30474719
[TBL] [Abstract][Full Text] [Related]
3. Efficient neutron capture therapy of glioblastoma with pteroyl-closo-dodecaborate-conjugated 4-(p-iodophenyl)butyric acid (PBC-IP).
Nishimura K; Kashiwagi H; Morita T; Fukuo Y; Okada S; Miura K; Matsumoto Y; Sugawara Y; Enomoto T; Suzuki M; Nakai K; Kawabata S; Nakamura H
J Control Release; 2023 Aug; 360():249-259. PubMed ID: 37356755
[TBL] [Abstract][Full Text] [Related]
4. Cyclic RGD-Functionalized
Kawai K; Nishimura K; Okada S; Sato S; Suzuki M; Takata T; Nakamura H
Mol Pharm; 2020 Oct; 17(10):3740-3747. PubMed ID: 32845640
[TBL] [Abstract][Full Text] [Related]
5. Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy.
Kikuchi S; Kanoh D; Sato S; Sakurai Y; Suzuki M; Nakamura H
J Control Release; 2016 Sep; 237():160-7. PubMed ID: 27422608
[TBL] [Abstract][Full Text] [Related]
6. Iodophenyl-conjugated closo-dodecaborate as a promising small boron molecule that binds to serum albumin and accumulates in tumor.
Nishimura K; Harrison S; Kawai K; Morita T; Miura K; Okada S; Nakamura H
Bioorg Med Chem Lett; 2022 Sep; 72():128869. PubMed ID: 35772634
[TBL] [Abstract][Full Text] [Related]
7. Tumor Cell-Specific 2'-Fluoro RNA Aptamer Conjugated with
Vorobyeva MA; Dymova MA; Novopashina DS; Kuligina EV; Timoshenko VV; Kolesnikov IA; Taskaev SY; Richter VA; Venyaminova AG
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298946
[TBL] [Abstract][Full Text] [Related]
8. Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy.
Pan XQ; Wang H; Shukla S; Sekido M; Adams DM; Tjarks W; Barth RF; Lee RJ
Bioconjug Chem; 2002; 13(3):435-42. PubMed ID: 12009931
[TBL] [Abstract][Full Text] [Related]
9. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy.
Ueno M; Ban HS; Nakai K; Inomata R; Kaneda Y; Matsumura A; Nakamura H
Bioorg Med Chem; 2010 May; 18(9):3059-65. PubMed ID: 20371186
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.
Shukla S; Wu G; Chatterjee M; Yang W; Sekido M; Diop LA; Müller R; Sudimack JJ; Lee RJ; Barth RF; Tjarks W
Bioconjug Chem; 2003; 14(1):158-67. PubMed ID: 12526705
[TBL] [Abstract][Full Text] [Related]
11. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy.
Wu G; Barth RF; Yang W; Lee RJ; Tjarks W; Backer MV; Backer JM
Anticancer Agents Med Chem; 2006 Mar; 6(2):167-84. PubMed ID: 16529539
[TBL] [Abstract][Full Text] [Related]
12. A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT).
Lamba M; Goswami A; Bandyopadhyay A
Chem Commun (Camb); 2021 Jan; 57(7):827-839. PubMed ID: 33399147
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas.
Tjarks W; Barth RF; Rotaru JH; Adams DM; Yang W; Kultyshev RG; Forrester J; Barnum BA; Soloway AH; Shore SG
Anticancer Res; 2001; 21(2A):841-6. PubMed ID: 11396173
[TBL] [Abstract][Full Text] [Related]
14. RGD Peptide-Conjugated Dodecaborate with the Ga-DOTA Complex: A Preliminary Study for the Development of Theranostic Agents for Boron Neutron Capture Therapy and Its Companion Diagnostics.
Mishiro K; Imai S; Ematsu Y; Hirose K; Fuchigami T; Munekane M; Kinuya S; Ogawa K
J Med Chem; 2022 Dec; 65(24):16741-16753. PubMed ID: 36512639
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application.
Achilli C; Grandi S; Ciana A; Guidetti GF; Malara A; Abbonante V; Cansolino L; Tomasi C; Balduini A; Fagnoni M; Merli D; Mustarelli P; Canobbio I; Balduini C; Minetti G
Nanomedicine; 2014 Apr; 10(3):589-97. PubMed ID: 24161383
[TBL] [Abstract][Full Text] [Related]
16. Assessing the effectiveness of fluorinated and α-methylated 3-boronophenylalanine for improved tumor-specific boron delivery in boron neutron capture therapy.
Hirano F; Kondo N; Murata Y; Sudani A; Temma T
Bioorg Chem; 2024 Jan; 142():106940. PubMed ID: 37939508
[TBL] [Abstract][Full Text] [Related]
17. Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy.
Li R; Zhang J; Guo J; Xu Y; Duan K; Zheng J; Wan H; Yuan Z; Chen H
Mol Pharm; 2020 Jan; 17(1):202-211. PubMed ID: 31763850
[TBL] [Abstract][Full Text] [Related]
18. Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter.
Miyabe J; Ohgaki R; Saito K; Wei L; Quan L; Jin C; Liu X; Okuda S; Nagamori S; Ohki H; Yoshino K; Inohara H; Kanai Y
J Pharmacol Sci; 2019 Mar; 139(3):215-222. PubMed ID: 30833090
[TBL] [Abstract][Full Text] [Related]
19. Ligand liposomes and boron neutron capture therapy.
Carlsson J; Kullberg EB; Capala J; Sjöberg S; Edwards K; Gedda L
J Neurooncol; 2003; 62(1-2):47-59. PubMed ID: 12749702
[TBL] [Abstract][Full Text] [Related]
20. Dodeca(carboranyl)-substituted closomers: toward unimolecular nanoparticles as delivery vehicles for BNCT.
Thomas J; Hawthorne MF
Chem Commun (Camb); 2001 Sep; (18):1884-5. PubMed ID: 12240362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
